Followers | 273 |
Posts | 55557 |
Boards Moderated | 24 |
Alias Born | 08/29/2007 |
Sunday, August 13, 2023 4:23:43 PM
Intellia Therapeutics Inc NASDAQ: NTLA
GoSymbol lookup
Health Care : Biotechnology | Small Cap BlendCompany profile
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent NTLA News
- Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) • GlobeNewswire Inc. • 10/07/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 09:29:43 PM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/03/2024 08:01:00 PM
- Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions • GlobeNewswire Inc. • 10/01/2024 11:30:00 AM
- Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting • GlobeNewswire Inc. • 09/12/2024 11:30:00 AM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/03/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:06:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:45:09 AM
- Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 08/08/2024 11:30:00 AM
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:17:08 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:13:01 PM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/24/2024 08:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/18/2024 08:03:06 PM
- Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm • PR Newswire (US) • 07/02/2024 04:53:00 PM
- Intellia Therapeutics Announces CFO Transition • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
- Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform • GlobeNewswire Inc. • 06/25/2024 07:30:00 PM
- Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 • GlobeNewswire Inc. • 06/17/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:24:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:21:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:20:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:18:01 PM
- Intellia Therapeutics Names Brian Goff to its Board of Directors • GlobeNewswire Inc. • 06/14/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:59:57 PM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM